Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 533 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiretroviral drugs Clear all
Terminated Phase 2 Interventional

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

NCT01026727
View directory record Official record
Conditions
HIV Infections
Interventions
MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 2Phase 3 Interventional

Maraviroc and NeuroAIDS Pathogenesis

NCT02159027
View directory record Official record
Conditions
AIDS Dementia Complex
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 12, 2026, 1:07 AM EDT
Completed No phase listed Observational

HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)

NCT00043641
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 12, 2026, 1:07 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating a Clinical Decision Support Tool for Antiretroviral Therapy Optimization

NCT07219862
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Clinical Decision Support System (CDSS), Antiretroviral Therapy, Highly Active, INDIVIDUALIZED THERAPY, AIDS (Acquired Immune Deficiency Syndrome), Personalized Medicine, Precision Medicine
Interventions
smART (Smart Antiretroviral Therapy Assistant), Traditional Prescribing resources
Other
Lead sponsor
Keck School of Medicine of USC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 12, 2026, 1:07 AM EDT
Completed No phase listed Observational

Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV

NCT00016783
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
16
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 4 Interventional

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

NCT00187551
View directory record Official record
Conditions
HIV Infections
Interventions
Interruption of enfuvirtide, enfuvirtide interrupton
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Not applicable Interventional

The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS

NCT00001024
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
8
States / cities
Palo Alto, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 12, 2026, 1:07 AM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 12, 2026, 1:07 AM EDT
Terminated Phase 4 Interventional Results available

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

NCT01194856
View directory record Official record
Conditions
HIV Infection, Mitochondrial Dysfunction
Interventions
Atazanavir/ritonavir, Efavirenz
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 12, 2026, 1:07 AM EDT
Terminated Phase 2 Interventional Results available

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

NCT04480554
View directory record Official record
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Not applicable Interventional

The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens

NCT00152061
View directory record Official record
Conditions
HIV Infections
Interventions
3TC and FTC
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

NCT04233879
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

NCT01625169
View directory record Official record
Conditions
HIV
Interventions
Etravirine pharmacokinetics in breast milk and plasma
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults

NCT00002427
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Stavudine, Didanosine
Drug
Lead sponsor
Research Institute for Genetic and Human Therapy
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 12, 2026, 1:07 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

NCT00000908
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
53
States / cities
Birmingham, Alabama • Harbor City, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 1 Interventional

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients

NCT01013415
View directory record Official record
Conditions
HIV-1 Infections
Interventions
HAART, T cells
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 1Phase 2 Interventional

Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment

NCT00012519
View directory record Official record
Conditions
HIV Infections
Interventions
indinavir sulfate, ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

NCT00098722
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc (UK-427,857), optimized background therapy
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
62
States / cities
Hobson City, Alabama • Garden Grove, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 12, 2026, 1:07 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Integrated HIV Prevention and HCV Care for PWID

NCT03981445
View directory record Official record
Conditions
HIV Prevention, HCV, Opioid Use, Intravenous Drug Usage
Interventions
ARTAS Adapted Patient Navigation, Adherence Counseling
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 64 Years
Enrollment
446 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 1 Interventional

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

NCT02652546
View directory record Official record
Conditions
HIV, Inflammation
Interventions
Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 12, 2026, 1:07 AM EDT
Completed No phase listed Observational

Observational Study of Treated and Untreated Acute and Early HIV-1 Infection

NCT00219934
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral therapy
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
16 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

NCT00040664
View directory record Official record
Conditions
HIV Infection
Interventions
ritonavir, fosamprenavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 1 Interventional Results available

Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

NCT05604209
View directory record Official record
Conditions
HIV Vaccine, HIV-1-infection
Interventions
ChAdOx1.HIVconsv62, ChAdOx1.tHIVconsv1, MVA.tHIVconsv4, MVA.tHIVconsv3, Placebo
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 12, 2026, 1:07 AM EDT
Completed Phase 4 Interventional

A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence

NCT00785616
View directory record Official record
Conditions
HIV Infection
Interventions
MEMS cap monitoring
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 12, 2026, 1:07 AM EDT